188264-84-8

Basic information

• Product Name: (S,S)-(+)-N,N'-BIS(3,5-DI-TERT-BUTYLSALICYLIDENE)-1,2-CYCLOHEXANEDIAMINO-COBALT(II)
• Synonyms: (1S,2S)-(+)-1,2-CYCLOHEXANEDIAMINO-N N'-BIS(3,5-DI-T-BUTYLSALICYLIDENE)COBALT(II);(1S,2S)-(+)-N,N'-BIS(3,5-DI-T-BUTYLSALICYDENE)-1,2-CYCLOHEXANEDIAMINOCOBALT(II);(S,S)-(+)-N,N'-BIS(3,5-DI-TERT-BUTYLSALICYLIDENE)-1,2-CYCLOHEXANEDIAMINO-COBALT(II);(1S,2S)-(+)-N,N-Bis(3,5-di-t-butylsalicylidene)-1,2-cyclohexanediaminocobalt(II);(S,S)-N,N'-BIS(3,5-DI-T-BUTYLSALICYLIDEN E) -1,2-CYCLOHEXANEDIAMINOCOBALT(II);(1S,2S)-(+)-1,2-Cyclohexanediamino-N,N'-bis(3,5-di-tert-butylsalicylidene)cobalt(II);(S,S)-(+)-N,N'-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminocobalt(II),98%;(S,S)-(+)-N,N'-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexane
• CAS NO: 188264-84-8
• Molecular Formula: C₃₆H₅₂CoN₂O₂
• Molecular Weight: 603.74
• Product Categories: Asymmetric Synthesis;Chiral Catalysts, Ligands, and Reagents;Kinetic ResolutionChiral Catalysts, Ligands, and Reagents;Privileged Ligands and Complexes;SALENs;fine chemicals, specialty chemicals, intermediates, electronic chemical, organic synthesis;Co;Jacobsen Metal
• Mol File: 188264-84-8.mol
• Article Data: 11

Chemical Properties

• Melting Point: >350 °C(lit.)
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: red-brown/Powder
• Density: g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: (S,S)-(+)-N,N'-BIS(3,5-DI-TERT-BUTYLSALICYLIDENE)-1,2-CYCLOHEXANEDIAMINO-COBALT(II)(CAS DataBase Reference)
• NIST Chemistry Reference: (S,S)-(+)-N,N'-BIS(3,5-DI-TERT-BUTYLSALICYLIDENE)-1,2-CYCLOHEXANEDIAMINO-COBALT(II)(188264-84-8)
• EPA Substance Registry System: (S,S)-(+)-N,N'-BIS(3,5-DI-TERT-BUTYLSALICYLIDENE)-1,2-CYCLOHEXANEDIAMINO-COBALT(II)(188264-84-8)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22
• Safety Statements: 36/37/39-36/37
• WGK Germany: 3
• Hazardous Substances Data: 188264-84-8(Hazardous Substances Data)

Usage

Chemical Properties

red to red-brown powder

Uses

(S,S)-(+)-N,N''-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminocobalt(ii) i sused as a catalyst for the hydrolytic kinetic resolution of terminal epoxides and the enantioselective ring opening of meso epoxides.

Upstream product

• 624-49-7 dimethylfumarate 
• 6147-53-1 cobalt(II) diacetate tetrahydrate 
• 135616-36-3 6,6'-((1E,1'E)-((1S,2S)-cyclohexane-1,2-diylbis(azanylylidene)) bis(methanylylidene))bis(2,4-di-tert-butylphenol) 
• 37942-07-7 3,5-di-tert-butyl-2-hydroxybenzaldehyde 
• 694-83-7 rac-diaminocyclohexane 
• 71-48-7 cobalt(II) acetate 
• 151433-25-9 (R,R)-N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine 
• 20439-47-8 (1R,2R)-1,2-diaminocyclohexane 
• 174829-13-1 =G87N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexane diamine+G2+'12'!J6 
• 151380-44-8 (+)-(S,S)-N,N'-bis[3,5-di-tert-butylsalicylidene]cyclohexane-1,2-diamine 

Downstream Products

• 1063614-36-7 [(S,S)-N,N-bis-(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamino-Co(III)-acetate] 
• 879093-91-1 [(rac-N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-diaminocyclohexane)Co(pentafluorobenzoate)] 

Relevant articles and documents

Tuning ligand electronics and peripheral substitution on cobalt salen complexes: Structure and polymerisation activity

A series of cobalt salen complexes, where salen represents an N 2O2 bis-Schiff-base bis-phenolate framework, are prepared, characterised and investigated for reversible-termination organometallic mediated radical polymerisation (RT-OMRP). The salen ligands contain a cyclohexane diimine bridge and systematically altered para-substituted phenoxide moieties as a method to examine the electronic impact of the ligand on complex structure and reactivity. The complexes are characterised by single crystal X-ray diffraction, cyclic voltammetry, X-ray photoelectron spectroscopy, electron paramagnetic resonance spectroscopy and computational methods. Structural studies all support a tailorable metal centre reactivity altered by the electron-donating ability of the salen ligand. RT-OMRP of styrene, methyl methacrylate and vinyl acetate is reported and suggests that cobalt-carbon bond strength varies with the ligand substitution. Competing β-hydrogen abstraction affords long-chain olefin-terminated polymer chains and well controlled vinyl acetate polymerisations, contrasting with the lower temperature associative exchange mechanism of degenerative transfer OMRP.

Catalytic activity of salenCo(III)OAc complex in the reaction of addition of carboxylic acids to terminal epoxides

The catalytic activity and regioselectivity were studied of the salenCo(III)OAc complex in the reaction of addition of aliphatic carboxylic acids to a series of terminal epoxides (epichlorohydrin, 1,2-epoxybutane, propylene oxide, tert-butyl glycidyl ether and 2,3-epoxypropyl phenyl ether). The reduction in the activity in the order: acetic > acrylic > methacrylic acid was found. The regioselectivity of the addition was independent on carboxylic acid nature and depended on the nature of the epoxide. The best regioselectivity for the addition to epichlorohydrin was observed. The catalytic activity and regioselectivity of salenCo(III)OAc were compared with those for chromium(III) acetate catalyst. The catalytic activity and regioselectivity were studied of the salenCo(III)OAc complex in the reaction of addition of aliphatic carboxylic acids (2) to a series of terminal epoxides (3). The reduction in the activity in the order: acetic > acrylic > methacrylic acid was found. The regioselectivity of the addition was independent on carboxylic acid nature and depended on the nature of the epoxide.

Switchable Polymerization Triggered by Fast and Quantitative Insertion of Carbon Monoxide into Cobalt–Oxygen Bonds

A strategy that uses carbon monoxide (CO) as a molecular trigger to switch the polymerization mechanism of a cobalt Salen complex [salen=(R,R)-N,N′-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine] from ring-opening copolymerization (ROCOP) of ep

OXYSTEROLS AND METHODS OF USE THEREOF

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and and R6 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.